Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 31

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 31
---
 first-hand as it holds a position in a private life sciences company Alzheon that is developing a therapeutic agent for AD patients who are APOE e4 carriers. The Company’s private investment position in Alzheon, which consists of 622,600 shares of Alzheon’s preferred stock, may create synergies for the post-merger Combined Company to potentially provide a diagnostic tool consisting of APOE genotype and miRNA panel testing for their therapeutic offering. Further, DiamiR’s technology and biomarker panels can facilitate identification of new indications for repurposed drugs, such as SACT-1 in our pipeline, an agent with previously unrecognized kinase inhibitory activity against MEK5/ERK5 signaling pathway that has shown promise in neuroblastoma. As described below, while building Aptorum’s pipeline via acquisitions and internal efforts, the Company’s executives have accumulated expertise in clinical studies and services. We recognize the importance of effective biomarkers for drug development, and therefore, deem DiamiR’s programs as highly synergistic with ours. As a post-merger Combined Company, the Company plans to utilize DiamiR’s biomarker panels in various clinical studies, including through collaborations with academic institutions and clinical centers in the US and other countries through Company Chief Executive Officer’s extensive global medical network, expanding therapeutic focus and geographical outreach for the Combined Company. In approving the Letter of Intent and the Merger, Company’s board of directors considered the pros and cons of the Merger versus other alternatives, which is likely a delisting of Company’s Class A ordinary shares from Nasdaq if the Merger is not completed, and the opportunities and risks presented with the Merger. In particular, Company’s board of directors took into account the following reasons, facts and circumstances in approving the Merger:

| ● | the potential for DiamiR’s product candidates in brain                                         
 health, cancer and inflammatory diseases to create long term value for Company’s stockholders; |

| ● | the potential synergies available when combining Company’s                                                        
 existing SACT-1 therapeutic program for neuroblastoma and potentially other indications with DiamiR’s technology; |

| ● | the potential enhanced ability to raise capital utilizing 
 a broader potential product portfolio;                    |

| ● | Company’s projected cash position and the difficulties                            
 the Company has encountered in raising sufficient capital on a stand-alone basis; |

| ● | the risks of continuing to operate Company on a stand-alone                                                                     
 basis, including uncertainty regarding Company’s product development and the